These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 23345306)

  • 1. Commentary on 'Small-sample behavior of novel phase I cancer trial designs'.
    Cheung YK
    Clin Trials; 2013 Feb; 10(1):86-7; discussion 88-92. PubMed ID: 23345306
    [No Abstract]   [Full Text] [Related]  

  • 2. Discussion of 'small-sample behavior of novel phase I cancer trial designs' by Assaf P Oron and Peter D Hoff.
    Carlin BP; Zhong W; Koopmeiners JS
    Clin Trials; 2013 Feb; 10(1):81-5; discussion 88-92. PubMed ID: 23345305
    [No Abstract]   [Full Text] [Related]  

  • 3. Small-sample behavior of novel phase I cancer trial designs.
    Oron AP; Hoff PD
    Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current issues in phase I trials: new study designs and informed consent procedures.
    Cavalli F; Sessa C
    Ann Oncol; 1999; 10 Suppl 6():147-8. PubMed ID: 10676566
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.
    Potter DM
    J Biopharm Stat; 2006; 16(5):579-604. PubMed ID: 17037260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose selection in phase I studies: why we should always go for the most effective.
    Haines IE
    J Clin Oncol; 2008 Jul; 26(21):3650-2; author reply 3652-3. PubMed ID: 18640947
    [No Abstract]   [Full Text] [Related]  

  • 7. Dose selection in phase I studies: why we should always go for the top.
    Sleijfer S; Wiemer E
    J Clin Oncol; 2008 Apr; 26(10):1576-8. PubMed ID: 18332465
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical trial design for phase 1 studies of drug combinations.
    Paller C
    Clin Adv Hematol Oncol; 2014 May; 12(5):335-7. PubMed ID: 25003492
    [No Abstract]   [Full Text] [Related]  

  • 9. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should We Preclude Phase 1 Clinical Trials From Enrolling Elderly Individuals?
    Balducci L
    Cancer Control; 2015 Apr; 22(2):232-4. PubMed ID: 26068770
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase 1 clinical trials nursing: determining safety and side effects on the road approval.
    Lindberg D
    ONS Connect; 2012 Jul; 27(7):10-4. PubMed ID: 22855983
    [No Abstract]   [Full Text] [Related]  

  • 13. [Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence].
    Kusaba H; Tamura T
    Gan To Kagaku Ryoho; 2000 May; 27(5):775-8. PubMed ID: 10832451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designs for single- or multiple-agent phase I trials.
    Conaway MR; Dunbar S; Peddada SD
    Biometrics; 2004 Sep; 60(3):661-9. PubMed ID: 15339288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose finding with continuous outcome in phase I oncology trials.
    Wang Y; Ivanova A
    Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A combination phase I/II study--dose escalation plan].
    Yamamoto N
    Gan To Kagaku Ryoho; 2000 Dec; 27(14):2267-74. PubMed ID: 11142175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
    Calvert AH; Plummer R
    Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive design may hasten clinical trials.
    Schmidt C
    J Natl Cancer Inst; 2007 Jan; 99(2):108-9. PubMed ID: 17227993
    [No Abstract]   [Full Text] [Related]  

  • 20. Statistical designs for early phases of cancer clinical trials.
    Guan S
    J Biopharm Stat; 2012; 22(6):1109-26. PubMed ID: 23075011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.